1. Home
  2. NAMS vs CCOI Comparison

NAMS vs CCOI Comparison

Compare NAMS & CCOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • CCOI
  • Stock Information
  • Founded
  • NAMS 2019
  • CCOI 1999
  • Country
  • NAMS Netherlands
  • CCOI United States
  • Employees
  • NAMS N/A
  • CCOI N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • CCOI Telecommunications Equipment
  • Sector
  • NAMS Health Care
  • CCOI Consumer Discretionary
  • Exchange
  • NAMS Nasdaq
  • CCOI Nasdaq
  • Market Cap
  • NAMS 2.5B
  • CCOI 2.4B
  • IPO Year
  • NAMS N/A
  • CCOI N/A
  • Fundamental
  • Price
  • NAMS $17.96
  • CCOI $47.45
  • Analyst Decision
  • NAMS Strong Buy
  • CCOI Buy
  • Analyst Count
  • NAMS 8
  • CCOI 8
  • Target Price
  • NAMS $42.88
  • CCOI $75.75
  • AVG Volume (30 Days)
  • NAMS 893.6K
  • CCOI 879.4K
  • Earning Date
  • NAMS 08-06-2025
  • CCOI 08-07-2025
  • Dividend Yield
  • NAMS N/A
  • CCOI 8.30%
  • EPS Growth
  • NAMS N/A
  • CCOI N/A
  • EPS
  • NAMS N/A
  • CCOI N/A
  • Revenue
  • NAMS $47,140,000.00
  • CCOI $936,884,000.00
  • Revenue This Year
  • NAMS N/A
  • CCOI $6.94
  • Revenue Next Year
  • NAMS N/A
  • CCOI $7.83
  • P/E Ratio
  • NAMS N/A
  • CCOI N/A
  • Revenue Growth
  • NAMS 586.97
  • CCOI N/A
  • 52 Week Low
  • NAMS $14.06
  • CCOI $43.65
  • 52 Week High
  • NAMS $27.29
  • CCOI $86.76
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 42.30
  • CCOI 44.01
  • Support Level
  • NAMS $20.06
  • CCOI $46.18
  • Resistance Level
  • NAMS $21.91
  • CCOI $49.47
  • Average True Range (ATR)
  • NAMS 1.41
  • CCOI 1.58
  • MACD
  • NAMS -0.20
  • CCOI 0.24
  • Stochastic Oscillator
  • NAMS 4.45
  • CCOI 55.28

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About CCOI Cogent Communications Holdings Inc.

Cogent carries over one fifth of the world's internet traffic over its network and is a broadband provider for businesses. Cogent's corporate customers are in high-rise office buildings, where the firm provides two types of connections: dedicated internet access, which connects them to the internet, and virtual private networking, which offers an internal network for employees in different locations. Cogent's corporate customers are exclusively in North America and account for nearly half of the firm's revenue. Cogent's netcentric customers include internet service providers and content providers, to which Cogent provides internet transit. They hand traffic to Cogent in data centers and rely on Cogent to deliver it. About half of netcentric revenue is from outside the US.

Share on Social Networks: